Natera Inc NTRA:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
After Hours: Last | 06/03/26 EDT212.64
+0.79 (+0.37%)
+0.79 (+0.37%)Volume
314,564
Close
211.85
-0.88 (-0.41%)
-0.88 (-0.41%)Volume
1,145,435
52 week range
131.81 - 256.36
- Open209.47
- Day High213.26
- Day Low204.16
- Prev Close212.73
- 52 Week High256.36
- 52 Week High Date01/07/26
- 52 Week Low131.81
- 52 Week Low Date08/01/25
Latest On Natera Inc
Key Stats
- Market Cap30.34B
- Shares Out143.22M
- 10 Day Average Volume1.51M
- Dividend-
- Dividend Yield-
- Beta1.55
Latest On Natera Inc
KEY STATS
- Open209.47
- Day High213.26
- Day Low204.16
- Prev Close212.73
- 52 Week High256.36
- 52 Week High Date01/07/26
- 52 Week Low131.81
- 52 Week Low Date08/01/25
- Market Cap30.34B
- Shares Out143.22M
- 10 Day Average Volume1.51M
- Dividend-
- Dividend Yield-
- Beta1.55
RATIOS/PROFITABILITY
- EPS (TTM)-1.64
- P/E (TTM)-129.33
- Fwd P/E (NTM)-156.69
- EBITDA (TTM)-265.876M
- ROE (TTM)-15.02%
- Revenue (TTM)2.501B
- Gross Margin (TTM)65.07%
- Net Margin (TTM)-9.05%
- Debt To Equity (MRQ)4.53%
EVENTS
- Earnings Date08/05/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORENatera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for...
Matthew Rabinowitz Ph.D.
Executive Chairman of the Board, Co-Founder
Steven Chapman
Chief Executive Officer, Director
John Fesko
President, Chief Business Officer
Michael Brophy
Chief Financial Officer
Address
13011 MCCALLEN PASS
BUILDING A SUITE 100
Austin, TX
78753
United States